PCMO L01—Setting Specifications for Biological Investigational Medicinal Products

Stephan O. Krause

doi:10.5731/pdajpst.2015.01065

Review ArticleReview

PCMO L01—Setting Specifications for Biological Investigational Medicinal Products

Stephan O. Krause

PDA Journal of Pharmaceutical Science and Technology September 2015, 69 (5) 569-589; DOI: https://doi.org/10.5731/pdajpst.2015.01065

Stephan O. Krause

AstraZeneca Biologics, 633 Research Court, Frederick, MD 21703, USA; 301-398-2108;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: krauses@medimmune.com

Article
Figures & Data
References
Info & Metrics
PDF

Article Information

vol. 69 no. 5 569-589

DOI

https://doi.org/10.5731/pdajpst.2015.01065

PubMed

26429107

Published By

Parenteral Drug Association (PDA)

Print ISSN

1079-7440

Online ISSN

1948-2124

History

Published online October 1, 2015.

Author Information

Stephan O. Krause*

AstraZeneca Biologics, 633 Research Court, Frederick, MD 21703, USA; 301-398-2108; krauses{at}medimmune.com

View Full Text

Cited By...

6 Citations
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

Expectations for Phase-Appropriate Drug Substance and Drug Product Specifications for Early-Stage Protein Therapeutics

Juliana Kretsinger, Neha Frantz, Scott A. Hart, Wayne P. Kelley, Bob Kitchen, Shawn Novick, Barbara Rellahan, Daniela Stranges, Corné J.M. Stroop, Ping Yin, Martin H. Gastens

Journal of Pharmaceutical Sciences 2019 108 4
Basic regulatory science behind drug substance and drug product specifications of monoclonal antibodies and other protein therapeutics

Patanachai K. Limpikirati, Sorrayut Mongkoltipparat, Thinnaphat Denchaipradit, Nathathai Siwasophonpong, Wudthipong Pornnopparat, Parawan Ramanandana, Phumrapee Pianpaktr, Songsak Tongchusak, Maoxin Tim Tian, Trairak Pisitkun

Journal of Pharmaceutical Analysis 2024 14 6
Effects of the COVID-19 pandemic: new approaches for accelerated delivery of gene to first-in-human CMC data for recombinant proteins

Hervé Broly, Jonathan Souquet, Alain Beck

mAbs 2023 15 1
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

John Geigert

2019
A Tolerance-based Approach for Validating Analytical Methods Using Design of Experiments

Gule Teri, Timothy Eveleigh

Journal of Pharmaceutical Innovation 2025 20 2
A pharmacology guided approach for setting limits on product-related impurities for bispecific antibody manufacturing

Sharmila Rajan, Junichiro Sonoda, Timothy Tully, Ambrose J. Williams, Feng Yang, Frank Macchi, Terry Hudson, Mark Z. Chen, Shannon Liu, Nicole Valle, Kyra Cowan, Thomas Gelzleichter

Journal of Pharmacological and Toxicological Methods 2018 94

PreviousNext

In This Issue

PDA Journal of Pharmaceutical Science and Technology

Vol. 69, Issue 5

September/October 2015

Table of Contents
Index by Author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following PCMO L01—Setting Specifications for Biological Investigational Medicinal Products

Message Subject (Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology

Message Body (Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 3 + 10 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

PCMO L01—Setting Specifications for Biological Investigational Medicinal Products

Stephan O. Krause

PDA Journal of Pharmaceutical Science and Technology Sep 2015, 69 (5) 569-589; DOI: 10.5731/pdajpst.2015.01065

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

PCMO L01—Setting Specifications for Biological Investigational Medicinal Products

Stephan O. Krause

PDA Journal of Pharmaceutical Science and Technology Sep 2015, 69 (5) 569-589; DOI: 10.5731/pdajpst.2015.01065

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
References
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

Development and qualification of a high-yield recombinant human Erythropoietin biosimilar

Google Scholar

Main menu

User menu

Search

PCMO L01—Setting Specifications for Biological Investigational Medicinal Products

Article Information

Author Information

Cited By...

In This Issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Readers

Author/Reviewer Information

Parenteral Drug Association, Inc.